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Hedgehog, meet Patched
H
edgehog protein and its receptor 
are made for each other, but 
even this perfect couple needs 
a little help to get together. Li et al. (1) 
reveal that a proteoglycan plays cupid for 
the molecules and sparks signal transduc-
tion through the Hedgehog pathway, a 
mechanism exploited by a type of child-
hood cancer.
During development, Hedgehog pro-
teins are sculptors, helping to mold the 
embryo’s limbs and other parts of the 
body. Later in life, however, the protein’s 
ability to spur cell division can promote 
basal cell carcinomas and other cancers, 
which often rev up the Hedgehog path-
way. Li et al. teased out a connection 
between Hedgehog proteins and rhabdo-
myosarcoma, a soft-tissue tumor that strikes 
children (2). Hedgehog proteins steer a 
cell’s fate by latching onto the membrane 
receptor Patched-1. Also participating in 
this encounter are proteoglycans known 
as glypicans (3). In previous work, the re-
searchers showed that glypican-3 curtails 
signaling by preventing Hedgehog pro-
teins from binding to 
Patched-1 (4). Another 
group has demonstrated 
that rhabdomyosarcoma 
cells often overproduce 
glypican-5 (5), raising the 
possibility that this proteo-
glycan promotes tumor 
growth by stimulating the 
Hedgehog pathway.
Li et al. put this idea 
to the test by modifying 
glypican-5 levels in rhabdomyosarcoma 
cells. They found that decreasing levels of 
glypican-5 by RNAi trimmed the amount 
of Gli1, a protein whose production is 
switched on by Hedgehog signaling. 
Boosting glypican-5 quantities had the 
opposite effect, raising Gli1 levels and 
speeding cell proliferation. Knowing that 
the primary cilium is necessary for Hedge-
hog signaling, Li et al. tracked glypi-
can-5 to the ciliary membrane, where 
they suspect it links up with Patched-1. 
However, glypican-3 didn’t show up in 
the cilium, which fi  ts with its proposed 
function in intercepting Hedgehog mole-
cules before they reach Patched-1.
How do glypican-5 molecules per-
form their job? “Basically, they are act-
ing like matchmakers,” says senior au-
thor Jorge Filmus. He and his colleagues 
determined that glypican-5 binds to Sonic 
Hedgehog, one of the mammalian Hedge-
hog proteins, and to Patched-1. Glypican-5 
also encouraged Sonic 
Hedgehog and Patched-1 
to stick together.
The team then investi-
gated whether one of the 
distinguishing features of 
glypicans—their glycosa-
minoglycan chains—af-
fects Hedgehog signaling. 
Glypican-5 carries chon-
droitin sulfate and hepa-
ran sulfate chains. En-
zymes that lop off the chondroitin sulfate 
molecules reduced glypican-5’s ability to 
bind to Patched-1, and enzymes that re-
move the heparan sulfates had an even 
stronger effect. That suggests both kinds 
of chains are needed for Hedgehog sig-
naling but that the heparan sulfate chains 
may be more important.
“This is a novel mechanism by which 
the Hedgehog signaling pathway can be ac-
tivated,” says Filmus. Yet how glypican-5 
serves as a matchmaker remains unresolved. 
The proteoglycan might coax Hedgehog 
proteins and Patched-1 to interact or might 
strengthen their bond once they’ve al-
ready linked up. The researchers think 
that mammalian cells can use their six dif-
ferent glypicans to fi  ne-tune  their re-
sponses to Hedgehog signals. “Cells use 
these glypicans to decide which are their 
favored interactions, which ones they re-
ally want to happen,” Filmus says. By 
making more glypican-3, for example, 
cells can reduce their sensitivity to Hedge-
hog proteins, or they can become more 
responsive by amplifying glypican-5.
The fi   ndings suggest two new ap-
proaches for rhabdomyosarcoma treat-
ment. Drugs that inhibit the Hedgehog 
pathway—usually by blocking a protein 
downstream of Patched-1—are already in 
clinical trials as therapies for several kinds 
of cancer. These compounds may also ben-
efi  t rhabdomyosarcoma patients. Another 
alternative, the researchers say, is develop-
ing novel drugs that target glypican-5.
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(Left to right) Jorge Filmus, Wen Shi, Mariana Capurro, and Fuchuan Li determined how glypican-5 
proteoglycans ﬁ  re up the Hedgehog pathway to promote the growth of rhabdomyosarcoma cells. 
At left, wild-type glypican-5 (red) settles in the primary cilium (green; arrow), which serves as an 
antenna for Hedgehog signaling. But glypican-5 molecules that lack glycosaminoglycan chains 
(right) largely remain outside the primary cilium.
“This is a novel 
mechanism 
by which the 
Hedgehog 
signaling 
pathway can be 
activated.”
Proteoglycan ensures that the Hedgehog protein and its receptor make a connection.
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